KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Esperion Therapeutics (ESPR) Shares Issued (2016 - 2026)

Esperion Therapeutics filings provide 8 years of Shares Issued readings, the most recent being $72.6 million for Q4 2025.

On a quarterly basis, Shares Issued fell 19.91% to $72.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $72.6 million, a 19.94% decrease, with the full-year FY2025 number at $72.6 million, down 19.94% from a year prior.
Shares Issued hit $72.6 million in Q4 2025 for Esperion Therapeutics, down from $90.6 million in the prior quarter.
In the past five years, Shares Issued ranged from a high of $90.6 million in Q4 2024 to a low of -$14.8 million in Q3 2024.
Median Shares Issued over the past 5 years was $9.0 million (2024), compared with a mean of $24.3 million.
Biggest five-year swings in Shares Issued: tumbled 171.38% in 2021 and later soared 1415.17% in 2022.
Esperion Therapeutics' Shares Issued stood at $6.5 million in 2021, then surged by 238.17% to $22.0 million in 2022, then surged by 138.44% to $52.4 million in 2023, then surged by 72.89% to $90.6 million in 2024, then decreased by 19.91% to $72.6 million in 2025.
The last three reported values for Shares Issued were $72.6 million (Q4 2025), $90.6 million (Q4 2024), and -$14.8 million (Q3 2024) per Business Quant data.